TY - JOUR
T1 - A Web site-based reporting system for monitoring home treatment during oral immunotherapy for food allergy
AU - Nachshon, Liat
AU - Goldberg, Michael R.
AU - Elizur, Arnon
AU - Levy, Michael B.
AU - Schwartz, Naama
AU - Katz, Yitzhak
N1 - Publisher Copyright:
© 2015 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Background Reactions during the home treatment phase of oral immunotherapy (OIT) are not uncommon. An ongoing accurate reporting of home treatment outcomes is crucial for the safety and success of OIT. Previous reports have shown that as few as 20% of patients are truly compliant with paper-based diaries. Objective To develop a Web site-based electronic reporting system (web-RS) for monitoring home treatment during OIT for food allergy. Methods A web-RS was developed and incorporated a thorough questionnaire querying for pertinent data including the dose(s) consumed, occurrence and details of adverse reactions, treatment(s), and relevant potential exacerbating factors. All patients enrolled in milk, peanut, or egg OIT programs for at least 4 weeks from November 2012 through January 2014 were introduced to web-RS (n = 157). Successful reporting through web-RS was defined by consecutive reporting during the first home treatment phase (24 days) after its introduction. Comparisons were made with a previous group of OIT-treated patients (n = 100) who reported by E-mail. Results Successful reporting was achieved by 142 of 157 patients (90.44%) in contrast to a 75% success rate with E-mail (P =.0009). The odds for successful reporting using web-RS were 3.1 (95% confidence interval 1.6-6.3) times higher compared with using E-mail. Mild reactions were reported more frequently with web-RS (P =.0032). Patient reports were constantly available in real time for medical staff review. No complaints regarding web-RS feasibility were reported. One risk factor for failure to use web-RS was a patient's prior successful OIT experience without using web-RS (P =.012). Conclusion A web-RS can be a powerful tool for improving OIT safety by achieving a high level of patient cooperation in reporting home treatment results.
AB - Background Reactions during the home treatment phase of oral immunotherapy (OIT) are not uncommon. An ongoing accurate reporting of home treatment outcomes is crucial for the safety and success of OIT. Previous reports have shown that as few as 20% of patients are truly compliant with paper-based diaries. Objective To develop a Web site-based electronic reporting system (web-RS) for monitoring home treatment during OIT for food allergy. Methods A web-RS was developed and incorporated a thorough questionnaire querying for pertinent data including the dose(s) consumed, occurrence and details of adverse reactions, treatment(s), and relevant potential exacerbating factors. All patients enrolled in milk, peanut, or egg OIT programs for at least 4 weeks from November 2012 through January 2014 were introduced to web-RS (n = 157). Successful reporting through web-RS was defined by consecutive reporting during the first home treatment phase (24 days) after its introduction. Comparisons were made with a previous group of OIT-treated patients (n = 100) who reported by E-mail. Results Successful reporting was achieved by 142 of 157 patients (90.44%) in contrast to a 75% success rate with E-mail (P =.0009). The odds for successful reporting using web-RS were 3.1 (95% confidence interval 1.6-6.3) times higher compared with using E-mail. Mild reactions were reported more frequently with web-RS (P =.0032). Patient reports were constantly available in real time for medical staff review. No complaints regarding web-RS feasibility were reported. One risk factor for failure to use web-RS was a patient's prior successful OIT experience without using web-RS (P =.012). Conclusion A web-RS can be a powerful tool for improving OIT safety by achieving a high level of patient cooperation in reporting home treatment results.
UR - http://www.scopus.com/inward/record.url?scp=84930039852&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2015.04.007
DO - 10.1016/j.anai.2015.04.007
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84930039852
SN - 1081-1206
VL - 114
SP - 510-515.e1
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 6
ER -